MolMed Likely to Seek Partner for Cancer Drug

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

(Corrects reference to Berlusconi family's holding.) Nov. 22 (Bloomberg) -- Claudio Bordignon, chief executive officer of Molecular Medicine SpA, an Italian biotechnology company whose biggest shareholder is the Berlusconi family, discusses the likelihood of a commercial partnership for its NGR-hTNF cancer treatment. He spoke yesterday in Milan with Bloomberg's Chiara Remondini. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change